KR100954851B1 - Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 - Google Patents
Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 Download PDFInfo
- Publication number
- KR100954851B1 KR100954851B1 KR1020070132389A KR20070132389A KR100954851B1 KR 100954851 B1 KR100954851 B1 KR 100954851B1 KR 1020070132389 A KR1020070132389 A KR 1020070132389A KR 20070132389 A KR20070132389 A KR 20070132389A KR 100954851 B1 KR100954851 B1 KR 100954851B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- fermented
- fermented ginseng
- concentrate
- present
- Prior art date
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 166
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 166
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 165
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 165
- 239000012141 concentrate Substances 0.000 title claims abstract description 69
- 239000000843 powder Substances 0.000 title claims abstract description 42
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 title abstract description 41
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 title abstract description 38
- 238000002360 preparation method Methods 0.000 title description 14
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 36
- 102000005936 beta-Galactosidase Human genes 0.000 claims abstract description 34
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 34
- 108010059820 Polygalacturonase Proteins 0.000 claims abstract description 33
- 108010093305 exopolygalacturonase Proteins 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 230000003178 anti-diabetic effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 239000003472 antidiabetic agent Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000002766 immunoenhancing effect Effects 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 229930182494 ginsenoside Natural products 0.000 description 17
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 229940089161 ginsenoside Drugs 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 244000309464 bull Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- BGHNZAWRRWLKPO-UHFFFAOYSA-N Ginsenoside F1 Natural products CC(=C)CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C BGHNZAWRRWLKPO-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- YDQIRODFTJGGMP-UHFFFAOYSA-N Prosapogenin Chemical compound C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC34)C)(CO)C1=CCC2C3(C)CC(O)C(O)C4(C)C(=O)OC1OC(CO)C(O)C(O)C1O YDQIRODFTJGGMP-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 241000880950 Viburnum dentatum Species 0.000 description 1
- ZNFRITHWVZXJRK-UHFFFAOYSA-N Vitalboside A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O ZNFRITHWVZXJRK-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- VTXFLUJNMHWAAT-UHFFFAOYSA-N alternoside VII Natural products CC1(C)CC(O)C2(CO)C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(=O)O)C(C)(C)C5CCC34C)C2C1 VTXFLUJNMHWAAT-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- XNGXWSFSJIQMNC-FIYORUNESA-N ginsenoside F1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNGXWSFSJIQMNC-FIYORUNESA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 108010001078 naringinase Proteins 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OILHVNROWDFZDW-UHFFFAOYSA-N prosapogenin Natural products CC1(C)CCC2(C(O)CC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6O)C(C)(C=O)C5CCC34C)C2C1)C(=O)O OILHVNROWDFZDW-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A23L3/44—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Fruits And Vegetables (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 고농도의 IH-901(20-O-β-D-글루코피라노실-20(S)-프로토파낙사다이올)을 함유하는 발효인삼농축액 또는 발효인삼분말의 제조방법에 관한 것으로, 보다 구체적으로 인삼추출액 또는 인삼액에 펙티나아제 및 베타갈락토시다아제를 가하여 인삼추출액을 발효시킴으로서 IH-901을 다량 함유하는 발효인삼농축액 또는 발효인삼분말을 제조하는 방법에 관한 것이다. 본 발명의 발효인삼농축액 또는 발효인삼분말의 제조방법은 고농도의 IH-901이 함유된 발효인삼농축액 또는 발효인삼분말을 간단하게 제조할 수 있는 방법이며, 또한 본 발명에 의해 제조된 발효인삼농축액 또는 발효인삼분말은 고농도의 IH-901을 함유하고 있어 기능성 식품 조성물로 효과적으로 이용될 수 있다.The present invention relates to a method for preparing fermented ginseng concentrate or fermented ginseng powder containing high concentration of IH-901 (20-O-β-D-glucopyranosyl-20 (S) -protopanaxadiol). Specifically, the present invention relates to a method for preparing fermented ginseng concentrate or fermented ginseng powder containing a large amount of IH-901 by fermenting ginseng extract by adding pectinase and beta galactosidase to ginseng extract or ginseng solution. Fermented ginseng concentrate or fermented ginseng powder production method of the present invention is a method that can easily prepare a fermented ginseng concentrate or fermented ginseng powder containing a high concentration of IH-901, and also the fermented ginseng concentrate prepared by the present invention or Fermented ginseng powder contains high concentration of IH-901 and can be effectively used as a functional food composition.
IH-901, 발효인삼농축액, 발효인삼분말 IH-901, Fermented Ginseng Concentrate, Fermented Ginseng Powder
Description
본 발명은 고농도의 IH-901(20-O-β-D-글루코피라노실-20(S)-프로토파낙사다이올)을 함유하는 발효인삼농축액 또는 발효인삼분말의 제조방법에 관한 것으로, 보다 구체적으로 인삼추출액 또는 인삼액에 펙티나아제 및 베타갈락토시다아제를 가하여 인삼추출액을 발효시킴으로서 IH-901을 다량 함유하는 발효인삼농축액 또는 발효인삼분말을 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing fermented ginseng concentrate or fermented ginseng powder containing high concentration of IH-901 (20-O-β-D-glucopyranosyl-20 (S) -protopanaxadiol). Specifically, the present invention relates to a method for preparing fermented ginseng concentrate or fermented ginseng powder containing a large amount of IH-901 by fermenting ginseng extract by adding pectinase and beta galactosidase to ginseng extract or ginseng solution.
인삼(the root of Panax ginseng C.A. Meyer. Araliaceae)은 중국, 한국, 일본 등의 아시아 국가에서 전통적으로 각종 질병의 치료에 사용되어 온 약재 중 하나이다. 특히 인삼의 주요 활성 성분인 진세노사이드(인삼 사포닌, saponin)는 항노화, 항염증, 중추 신경계와 심혈관계 및 면역계에서의 항산화 활성(Wu JY, et al., J. Immunol., 148:1519-25, 1992; Lee FC., Facts about ginseng, the elixir of life . Hollyn International. New Jersey, 1992; Huang KC., The pharmacology of Chinese herbs . CRC Press. Florida, 1999), 항당뇨 활성(Chang HM., Pharmacology and application of Chinese material medica. Vol1. World Scientific. Singapore, 1986) 및 항종양 활성(Sato K, et al.,Biol. Pharm. Bull. 17:635-9, 1994; Mochizuki M, et al., Biol. Pharm. Bull. 18:1197-1202, 1995) 등과 같은 다양한 생리활성을 가지는 것으로 알려져 있다.Ginseng (the root of Panax ginseng CA Meyer.Araliaceae) is one of the traditional medicines used in the treatment of various diseases in Asian countries such as China, Korea and Japan. In particular, ginsenoside (ginseng saponin, saponin), the main active ingredient of ginseng, has anti-aging, anti-inflammatory, antioxidant activity in the central nervous system and cardiovascular and immune system (Wu JY, et al., J. Immunol. , 148: 1519 -25, 1992;.. Lee FC , Facts about ginseng, the elixir of life Hollyn International . New Jersey, 1992; Huang KC., The pharmacology of Chinese herbs . CRC Press . Florida, 1999), antidiabetic activity (Chang HM., Pharmacology and application of Chinese material medica. Vol 1. World Scientific . Singapore, 1986) and anti-tumor activity (Sato K, et al., Biol. Pharm. Bull . 17: 635-9, 1994; Mochizuki M, et al., Biol. Pharm. Bull. 18: 1197-1202, 1995).
한편, 상기 진세노사이드는 섭취 후 사람의 장내 미생물에 의해 대사되어 그 대사산물 또한 다양한 생리활성을 가지는 것으로 알려져 있다(Karikura M, et al., Chem. Pharm. Bull, 39:2357-61, 1991; Kanaoda M, et al., J. Tradit. Med. 11:241-5, 1994; Akao T, et al., Biol. Pharm. Bull. 21:245-9, 1998). 예를 들어, 프로토파낙사디올계 진세노사이드인 Rb1, Rb2, Rc는 사람의 장내 미생물에 의해 IH-901(20-O-β-D-글루코피라노실(glucopyranosyl)-20(S)-프로토파낙사디올)로 대사되고(Hasegawa H, et al., Planta Medica 63:463-40, 1997; Tawab MA, et al., Drug Metab. Dispos. 31:1065-71, 2003), 프로토파낙사트리올계 진세노사이드인 Re와 Rg1은 진세노사이드 Rh1이나 진세노사이드 F1으로 대사되며(Hasegawa H, et al., Planta Medica 62:453-7, 1996; Tawab MA, et al., Drug Metab. Dispos. 31:1065-71, 2003), 상기 대사 산물인 IH-901, Rh1 및 F1은 다양한 생리활성을 나타내게 된다.On the other hand, the ginsenosides are metabolized by human intestinal microorganisms after ingestion and their metabolites are also known to have various physiological activities (Karikura M, et al., Chem. Pharm. Bull , 39: 2357-61, 1991 Kanaoda M, et al., J. Tradit.Med . 11: 241-5, 1994; Akao T, et al., Biol. Pharm. Bull. 21: 245-9, 1998). For example, Rb1, Rb2, and Rc, the protoparnaxadiol-based ginsenosides, are identified by IH-901 (20-O-β-D-glucopyranosyl-20 (S) -prototype by human intestinal microorganisms. Panaxanadiol) (Hasegawa H, et al., Planta Medica 63: 463-40, 1997; Tawab MA, et al., Drug Metab. Dispos . 31: 1065-71, 2003) All ginsenosides Re and Rg1 are metabolized to ginsenoside Rh1 or ginsenoside F1 (Hasegawa H, et al., Planta Medica 62: 453-7, 1996; Tawab MA, et al., Drug Metab. . 31: 1065-71, 2003), the metabolite, IH-901, Rh1, and F1 is to exhibit the various physiological activities.
특히 상기 IH-901은 주로 항당뇨(Yun Suk Choi et.al., J Ginseng Res . 31(2): 79-85, 2007) 및 면역증강 작용을 하는 것으로 알려져 있으며, 또한 종양의 침입을 막거나 염색체 변형과 종양형성을 예방함으로서 항전이 또는 항암 효과를 유도한다고 알려져 있다(Wakabayashi C, et al., Oncol. Res. 9:411-7, 1998; Lee SJ, et al., Cancer Lett. 144:39-43, 1999).In particular, the IH-901 is mainly anti-diabetic (Yun Suk Choi et.al., J Ginseng Res . 31 (2): 79-85, 2007) and are known to have an immunopotentiating effect and also to induce anti-metastatic or anti-cancer effects by preventing tumor invasion or preventing chromosomal alterations and tumor formation (Wakabayashi C, et al., Oncol. Res. 9: 411-7, 1998; Lee SJ, et al., Cancer Lett. 144: 39-43, 1999).
이러한 이유로 상기 진세노사이드를 상기 대사산물로 전환시키려는 노력들이 광범위하게 시도되었다. 일부 연구자들은 화학적 합성, 약산 가수분해, 알칼리 분해 등으로 진성 프로사포제닌(genuine prosapogenin) 또는 사포제닌을 생산하려 하였다(Han BH, et al., Planta Medica 44:146-9, 1982; Chen Y, et al., Chem. Pharm. Bull. 35: 1653-5, 1987; Elyakov GB, et al., Synthesis of the ginseng glycosides and their analogs. Proc. 6th Int. Ginseng Symp. Seoul 74-83, 1993). 그러나 상기 방법들은 에피머화(epimerization), 수화(hydration), 히드록실화(hydroxylation)등과 같은 여러 가지 부반응을 야기하므로, 최근에는 효소(Ko SR, et al., Biosci. Biotechnol. Biochem. 64:2739-43, 2000; Ko SR, et al., Planta Med. 69:285-6, 2003)와 장내세균(Hasegawa H, et al., Planta Medica 63:463-40, 1997; Bae EA, et al., J. Microbial. Biotechnol. 13:9-14, 2003) 등을 이용한 온화한 조건에서 진세노사이드를 전환시키는 방법들이 다양하게 연구되고 있다.For this reason, efforts have been extensively attempted to convert the ginsenosides to the metabolites. Some researchers have attempted to produce genuine prosapogenin or sapogenin by chemical synthesis, weak acid hydrolysis, alkali decomposition (Han BH, et al., Planta Medica 44: 146-9, 1982; Chen Y, et al., Chem. Pharm. Bull. 35: 1653-5, 1987; Elyakov GB, et al., Synthesis of the ginseng glycosides and their analogs.Proc . 6th Int. Ginseng Symp. Seoul 74-83, 1993). However, since these methods cause various side reactions such as epimerization, hydration, hydroxylation, etc., recently, enzymes (Ko SR, et al., Biosci. Biotechnol. Biochem. 64: 2739) -43, 2000; Ko SR, et al., Planta Med. 69: 285-6, 2003) and enterobacteria (Hasegawa H, et al., Planta Medica 63: 463-40, 1997; Bae EA, et al. , J. Microbial , Biotechnol. 13: 9-14, 2003), and various methods for converting ginsenosides under mild conditions have been studied.
특히 상기 진세노사이드로부터 상기 IH-901을 제조하기 위해 효소를 이용한 방법들이 연구되어 왔는데, 구체적으로 다이올계 진세노사이드를 나린지나제 효소로 가수 분해시켜 IH-901을 제조하는 방법이나, 상기 다이올계 진세노사이드를 쥐에 경구 투여한 후 대장에서 분해시켜 IH-901을 제조하는 방법이 개발되었다. 그러나 상기 제조방법은 IH-901의 생성 수율이 극히 낮을 뿐만 아니라 다양한 2차 대사산물이 생성되어 고순도의 IH-901을 생산하는데 문제점이 있었다(Karikura et al., Chem. Pharm. Bull. 38: 2859, 1990).In particular, methods have been studied using enzymes to prepare the IH-901 from the ginsenoside. Specifically, a method of preparing IH-901 by hydrolyzing a diol-based ginsenoside with naringinase enzyme or the die A method for preparing IH-901 has been developed by orally administering all-type ginsenosides to mice and then digesting them in the large intestine. However, the production method was not only extremely low production yield of IH-901 but also various secondary metabolites were produced to produce high purity IH-901 (Karikura et al., Chem. Pharm. Bull. 38: 2859 , 1990).
이에 따라 베타갈락토시다아제 효소를 진세노사이드 Rb1, Rb2, Rc, Rd 또는 이들의 혼합물과 반응시켜 상기 IH-901을 제조하는 방법(특허출원번호: 2002-32039호)이 개발되었고, 나린지나제 및 펙티나아제를 정제된 진세노사이드와 반응시켜 상기 IH-901을 제조하는 방법(특허출원번호: 2001-67964호)이 개발되었으며, 세룰라제 또는 베타갈락토시다아제 효소를 진세노사이드 Rb1 , Rb2 , Rc, Rd 또는 이들의 혼합물과 반응시켜 상기 IH-901을 제조하는 방법(특허출원번호: 2000-43170호)이 개발되었다.Accordingly, a method of preparing IH-901 by reacting beta galactosidase enzyme with ginsenosides Rb1, Rb2, Rc, Rd or a mixture thereof (Patent Application No. 2002-32039) was developed. A method for preparing IH-901 by reacting an agent and pectinase with purified ginsenosides (Patent Application No. 2001-67964) has been developed, and the enzyme ginsenosides with cerulases or beta galactosidase enzymes have been developed. A method of preparing IH-901 by reacting with Rb1, Rb2, Rc, Rd or mixtures thereof (Patent Application No. 2000-43170) has been developed.
상기 제조방법은 인삼농축액을 주원료로 하기 보다는 각각의 진세노사이드를 분리하여 사용하고 있어 그 제조방법이 매우 복잡하며, IH-901을 다량으로 함유한 발효인삼농축액을 제조하기에는 부적합한 방법이다. 따라서 상기 방법에 의해 제조된 발효물은 식품으로 직접 사용하기 어려우며 또한 IH-901의 생성량이 적어 그 효능을 기대하기 어려운 문제점이 있었다.The manufacturing method is used to separate each ginsenoside rather than the ginseng concentrate as a main raw material is very complicated, the method is not suitable for the production of fermented ginseng concentrate containing a large amount of IH-901. Therefore, the fermented product prepared by the above method is difficult to use directly as a food, and there is a problem that the production amount of IH-901 is small and it is difficult to expect its efficacy.
본 발명자들은 상기와 같은 문제점을 극복하고 고농도의 IH-901이 함유된 발효인삼농축액 또는 발효인삼분말을 제조하는 방법에 관하여 연구하던 중, 펙티나아제 및 베타갈락토시다아제를 특정한 조건으로 혼합하고, 이를 인삼추출액 또는 인삼액에 가하여 특정한 조건에서 발효시킴으로서 고농도의 IH-901이 함유된 발효인삼농축액 또는 발효인삼분말을 제조할 수 있음을 확인하여 본 발명을 완성하였다.The present inventors overcome the above problems and while studying the method for producing a fermented ginseng concentrate or fermented ginseng powder containing a high concentration of IH-901, mixing the pectinase and beta galactosidase under specific conditions The present invention was completed by confirming that fermented ginseng concentrate or fermented ginseng powder containing high concentration of IH-901 by fermentation under specific conditions was added to ginseng extract or ginseng solution.
따라서 본 발명의 과제는 고농도의 IH-901이 함유된 발효인삼농축액 또는 발효인삼분말의 제조방법을 제공하는 것이다.Accordingly, an object of the present invention is to provide a method for preparing fermented ginseng concentrate or fermented ginseng powder containing high concentration of IH-901.
상기와 같은 과제를 해결하기 위하여, 본 발명은 인삼에 물 또는 유기용매를 가하여 인삼추출액을 제조하고, 그 인삼추출액에 펙티나아제와 베타갈락토시다아제를 혼합하여 가하고, 그 인삼추출액을 발효시킨 후, 농축하는 단계를 포함하는 것을 특징으로 하는 발효인삼농축액의 제조방법을 제공한다.In order to solve the above problems, the present invention is prepared by adding water or an organic solvent to the ginseng to prepare a ginseng extract, mixed with the pectinase and beta galactosidase to the ginseng extract, fermented the ginseng extract Thereafter, it provides a method for producing a fermented ginseng concentrate, comprising the step of concentrating.
또한 본 발명은 인삼에 물을 가하여 인삼액을 제조하고, 그 인삼액에 펙티나아제와 베타갈락토시다아제를 혼합하여 가한 후 발효시킨 다음, 발효된 인삼액을 물 또는 유기용매를 사용하여 추출한 후, 농축하는 단계를 포함하는 것을 특징으로 하는 발효인삼농축액의 제조방법을 제공한다.In addition, the present invention is prepared by adding water to the ginseng to prepare a ginseng solution, mixed with the pectinase and beta galactosidase to the ginseng solution and then fermented, then extracted the fermented ginseng solution using water or an organic solvent Thereafter, it provides a method for producing a fermented ginseng concentrate, comprising the step of concentrating.
또한 본 발명은 상기 제조된 발효인삼농축액을 감압 건조 또는 동결 건조하는 것을 특징으로 하는 발효인삼분말의 제조방법을 제공한다.The present invention also provides a method for producing a fermented ginseng powder, characterized in that the dried fermented ginseng concentrate is dried under reduced pressure or freeze-dried.
또한 본 발명은 상기 제조된 발효인삼농축액 또는 발효인삼분말을 유효성분으로 함유하는 것을 특징으로 하는 기능성 식품 조성물을 제공한다.In another aspect, the present invention provides a functional food composition comprising the fermented ginseng concentrate or fermented ginseng powder prepared as an active ingredient.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발효인삼농축액의 제조방법은 인삼에 물 또는 유기용매를 가하여 인삼추출액을 제조하는 (a)단계와, 상기 (a)단계에서 제조된 인삼추출액에 펙티나아제와 베타갈락토시다아제를 혼합하여 가하는 (b)단계와, 상기 (b)단계를 거친 인삼추출액을 발효시킨 후, 농축하는 (c)단계를 포함하는 것을 특징으로 한다.In the method of preparing the fermented ginseng concentrate of the present invention, the ginseng extract prepared by adding water or an organic solvent to ginseng is prepared, and the pectinase and beta galactosidase are prepared in the ginseng extract prepared in step (a). After mixing and adding (b) and fermenting the ginseng extract after the step (b), characterized in that it comprises a step (c) of concentration.
이하 본 발명의 발효인삼농축액의 제조방법을 단계별로 보다 상세히 설명한다.Hereinafter, the method of preparing the fermented ginseng concentrate of the present invention will be described in detail step by step.
상기 (a)단계에서 인삼은 이에 한정되지는 않지만 바람직하게는 미삼, 백삼, 수삼, 건삼, 홍삼, 태극삼, 이들의 추출액, 이들의 분말 및 이들의 조합으로 이루 어진 군에서 선택된 것을 말하며, 본 발명의 일실시예에서는 미삼, 백삼, 수삼 및 인삼분말을 사용하였다(<실시예 1> 참조).In the step (a) ginseng is not limited to this, but preferably selected from the group consisting of the ginseng, white ginseng, ginseng, dried ginseng, red ginseng, Taegeuk ginseng, extracts thereof, powders thereof, and combinations thereof. In one embodiment of the ginseng, white ginseng, ginseng and ginseng powder was used (see <Example 1>).
상기 (a)단계에서 유기용매는 이에 한정되지는 않지만 바람직하게는 아세토니트릴, 디옥산, 디메틸 설폭사이드, 메탄올, 에탄올, 1-프로판올, 2-프로판올 및 이들의 조합으로 이루어진 군에서 선택된 것을 말하며, 본 발명의 일실시예에서는 주정(에탄올)을 사용하였다(<실시예 1> 참조).In the step (a), the organic solvent is not limited thereto, but preferably refers to one selected from the group consisting of acetonitrile, dioxane, dimethyl sulfoxide, methanol, ethanol, 1-propanol, 2-propanol, and combinations thereof. In one embodiment of the present invention, alcohol (ethanol) was used (see <Example 1>).
상기 (a)단계에서 인삼추출액을 제조하는 것은 상기 인삼에 물 또는 상기 유기용매를 가하여 당업자에게 공지된 방법에 의해 인삼추출액을 제조하는 것을 말하며, 이 때 물 및 상기 유기용매를 적절히 혼합하여 사용하는 것이 바람직하다. 상기 유기용매를 혼합하여 사용하는 것은 효소반응에 의해 생성되는 중간 반응물의 용해도를 증가시킴으로서 최종적으로 발효인삼농축액 또는 발효인삼분말의 IH-901 함량을 향상시킬 수 있기 때문이다. 따라서 본 발명의 일실시예에서는 인삼에 물과 에탄올을 1:1의 비율로 혼합하고 이를 전체 기질에 대하여 500%를 가하여 인삼추출액을 제조하였다(<실시예 1> 참조).Preparing ginseng extract in the step (a) refers to the preparation of the ginseng extract by the method known to those skilled in the art by adding water or the organic solvent to the ginseng, wherein the water and the organic solvent is used by appropriately mixing It is preferable. The mixing and use of the organic solvent is because the solubility of the intermediate reactants produced by the enzymatic reaction can be increased to finally improve the content of IH-901 in the fermented ginseng concentrate or the fermented ginseng powder. Therefore, in one embodiment of the present invention, ginseng extract was prepared by mixing water and ethanol at a ratio of 1: 1 and adding 500% to the total substrate (see <Example 1>).
상기 (b)단계에서 상기 (a)단계에 의해 제조된 인삼추출액에 펙티나아제 및 베타갈락토시다아제를 가하는 것은 펙티나아제 및 베타갈락토시다아제를 1:1~100의 비율로 혼합하고 이를 상기 (a)단계에서 제조된 인삼추출액의 전체 중량에 대하여 1~50중량%를 가하는 것을 말한다. 특히 펙티나아제 또는 베타갈락토시다아제를 각각 단독으로 가한 경우, 펙티나아제 및 베타갈락토시다아제를 상기와 같이 혼합하여 가하는 경우에 비해 최종적으로 발효인삼농축액의 IH-901 함량이 비교적 적음을 확인하였다(<실험예 1>참조). 따라서 펙티나아제 및 베타갈락토시다아제를 상기와 같이 혼합하여 가하는 것이 본 발명의 특징 중 하나이다.Adding the pectinase and beta galactosidase to the ginseng extract prepared by the step (a) in the step (b) is a mixture of pectinase and beta galactosidase in a ratio of 1: 1 to 100, and This refers to adding 1 to 50% by weight relative to the total weight of the ginseng extract prepared in step (a). In particular, when the pectinase or beta galactosidase is added alone, the content of IH-901 in the fermented ginseng concentrate is relatively lower than the case where the pectinase and beta galactosidase are mixed and added as described above. It confirmed (see <Experimental example 1>). Therefore, it is one of the features of the present invention to add the pectinase and beta galactosidase by mixing as described above.
특히 본 발명자들은 수많은 실험을 통하여 인삼추출액에 상기 펙티나아제 및 베타갈락토시다아제를 상기 비율로 하여 상기 양으로 가하는 것이 최종적으로 발효인삼농축액 또는 발효인삼분말의 IH-901 함량을 가장 높일 수 있음을 밝혀내었다.In particular, the present inventors can increase the IH-901 content of the fermented ginseng concentrate or fermented ginseng powder by adding the pectinase and the beta galactosidase to the ginseng extract in the above amount through the numerous experiments. Revealed.
상기 (c)단계에서 상기 (b)단계를 거친 인삼추출액을 발효시키는 것은 인삼추출액에 상기와 같이 펙티나아제와 베타갈락토시다아제를 혼합하여 가한 후, pH 3~8 및 10~70℃에서 1~72시간동안 발효시키는 것을 말한다. 상기 pH는 상기 펙티나아제 및 베타갈락토시다아제 효소가 활성을 유지하는 범위라면 한정되지 않으나, 바람직하게는 pH 3~8일 수 있으며 가장 바람직하게는 pH 4~6일 수 있다. 상기 pH는 상기 효소의 활성을 저하시키지 않는다면 이에 한정되지 않지만, 상기 인삼추출액에 포스페이트, 구연산, 구연산 나트륨 완충용액을 가하여 조절될 수 있다. 또한 상기 반응온도는 상기 펙티나아제 및 베타갈락토시다아제효소가 활성을 유지하는 범위라면 한정되지 않으나 바람직하게는 10~70℃일 수 있으며 가장 바람직하게는 50℃일 수 있다. 또한 상기 반응시간은 상기 효소가 활성을 유지하는 기간이라면 한정되지 않으나 바람직하게는 1~72시간일 수 있으며 가장 바람직하게는 48시간일 수 있다. 본 발명의 일실시예에서는 상기 (a)단계에서 제조된 인삼추출액에 구연산을 가하여 pH 3~4가 되도록 조절한 후, 상기 펙티나아제와 베타갈락토시다아제를 혼합하여 가한 후, 50℃에서 48 또는 72시간동안 발효시켰다(<실시예 1> 참조).Fermenting the ginseng extract from the step (c) in the step (b) is added to the ginseng extract by mixing the pectinase and beta galactosidase as described above, at pH 3 ~ 8 and 10 ~ 70 ℃ It means fermentation for 1 ~ 72 hours. The pH is not limited as long as the pectinase and beta galactosidase enzymes maintain activity, but may be preferably pH 3-8, and most preferably pH 4-6. The pH is not limited so long as it does not lower the activity of the enzyme, but may be adjusted by adding phosphate, citric acid, sodium citrate buffer solution to the ginseng extract. In addition, the reaction temperature is not limited as long as the pectinase and beta galactosidase enzyme maintains activity, but preferably 10 to 70 ° C, and most preferably 50 ° C. In addition, the reaction time is not limited as long as the enzyme maintains activity, but may be preferably 1 to 72 hours, and most preferably 48 hours. In one embodiment of the present invention, after adding the citric acid to the ginseng extract prepared in step (a) to adjust the pH to 3 ~ 4, the pectinase and beta galactosidase is added to the mixture, at 50 ℃ Fermentation was carried out for 48 or 72 hours (see <Example 1>).
상기 (c)단계에서 발효된 인삼추출물을 농축하는 것은 이에 한정되지 않지만 발효된 인삼추출물을 그대로 농축하거나 원심 분리하여 상등액만을 취해 농축할 수 있으며 통상적으로 사용하는 진공감압농축기를 사용하여 수행할 수 있다. 본 발명의 일실시예에서는 상기 (c)단계에서 발효된 인삼추출물을 80℃에서 감압 농축하였다(<실시예 1> 참조).Concentrating the ginseng extract fermented in the step (c) is not limited to this, but the concentrated fermented ginseng extract as it is or can be concentrated by taking only the supernatant by centrifugation, it can be carried out using a vacuum decompression concentrator. . In one embodiment of the present invention, the ginseng extract fermented in step (c) was concentrated under reduced pressure at 80 ℃ (see <Example 1>).
또한 본 발명의 발효인삼농축액의 제조방법은 인삼에 물을 가하여 인삼액을 제조하고 상기 제조된 인삼액에 펙티나아제 및 베타갈락토시다아제를 가하여 발효시킨 다음, 발효된 인삼액을 물 또는 유기용매를 사용하여 추출한 후, 농축하는 단계를 포함하는 것을 특징으로 한다. 보다 구체적으로 통상의 방법에 따라 인삼에 물을 가하여 인삼액을 제조한 후, 상기 기술한 것과 동일한 조건에서 상기 제조된 인삼액에 펙티나아제 및 베타갈락토시다아제를 가하여 발효시킨 다음, 발효된 인삼액을 물 또는 유기용매를 사용하여 상기 기술한 것과 동일한 조건에서 추출한 후, 농축하는 단계를 포함하는 것을 특징으로 한다.In addition, the method for preparing a fermented ginseng concentrate of the present invention is prepared by adding water to ginseng to prepare a ginseng solution, and adding fermented ginseng solution to pectinase and beta galactosidase, and then fermenting the ginseng solution to water or organic matter. After extraction using a solvent, characterized in that it comprises the step of concentrating. More specifically, ginseng solution was prepared by adding water to ginseng according to a conventional method, followed by fermentation by adding pectinase and beta galactosidase to the prepared ginseng solution under the same conditions as described above. Ginseng solution is extracted under the same conditions as described above using water or an organic solvent, characterized in that it comprises the step of concentrating.
본 발명의 발효인삼분말의 제조방법은 상기와 같이 제조된 발효인삼농축액을 감압 건조 또는 동결 건조하는 것을 특징으로 한다. 상기 감압 건조 또는 동결 건조하기 위하여 통상적으로 사용하는 열풍건조기 또는 동결 건조기를 사용하여 수행할 수 있다.The method for preparing fermented ginseng powder of the present invention is characterized in that the fermented ginseng concentrate prepared as described above is dried under reduced pressure or lyophilized. It may be carried out using a hot air dryer or a freeze dryer which is commonly used for drying under reduced pressure or freeze drying.
본 발명의 기능성 식품 조성물은 본 발명에 의한 발효인삼농축액 또는 발효인삼분말을 유효성분으로 함유하는 것을 특징으로 한다. 상기 본 발명에 의한 발효인삼농축액 또는 발효인삼분말은 면역증강, 항당뇨 및 항암 효과가 우수한 것으로 알려진 IH-901을 다량 함유하고 있어, 이를 유효성분으로 함유하는 본 발명의 기능성 식품 조성물 또한 면역증강, 항당뇨 및 항암 효과가 우수함은 자명하다.Functional food composition of the present invention is characterized by containing the fermented ginseng concentrate or fermented ginseng powder according to the present invention as an active ingredient. The fermented ginseng concentrate or fermented ginseng powder according to the present invention contains a large amount of IH-901 known to have excellent immunity enhancement, antidiabetic and anticancer effects, and the functional food composition of the present invention containing it as an active ingredient also enhances immunity, It is obvious that the antidiabetic and anticancer effects are excellent.
본 발명의 기능성 식품 조성물은 본 발명에 의한 발효인삼농축액 또는 발효인삼분말이나 이들의 혼합물을 그대로 첨가하거나 당업자에게 공지된 방법에 따라 가공하여, 다른 식품 성분을 추가적으로 첨가함으로서 제조될 수 있다. 상기 본 발명에 의한 발효인삼농축액 또는 발효인삼분말의 첨가양은 기능성 식품 조성물의 사용 목적에 따라 당업자에 의해 적합하게 결정될 수 있다. 일반적으로 본 발명의 발효인삼농축액 또는 발효인삼분말은 기능성 식품 조성물 총 중량에 대하여 0.1 내지 100중량%로 함유하는 것이 바람직하다. 그러나 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있음은 자명하다.The functional food composition of the present invention can be prepared by adding fermented ginseng concentrate or fermented ginseng powder or a mixture thereof according to the present invention as it is or by processing according to methods known to those skilled in the art, and additionally adding other food ingredients. The added amount of the fermented ginseng concentrate or fermented ginseng powder according to the present invention can be appropriately determined by those skilled in the art according to the purpose of use of the functional food composition. In general, the fermented ginseng concentrate or fermented ginseng powder of the present invention is preferably contained in 0.1 to 100% by weight based on the total weight of the functional food composition. However, in the case of long-term intake for the purpose of health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
본 발명의 기능성 식품 조성물에 첨가될 수 있는 식품 성분으로는 기능성 식품의 종류에 따라 달라질 수 있으며 본 발명에 의한 발효인삼농축액 또는 발효인삼분말과 혼합하는 경우 부작용을 일으키지 않는 성분이라면 이에 제한되지 않는다.The food ingredients that may be added to the functional food composition of the present invention may vary depending on the type of functional food, and are not limited thereto as long as they do not cause side effects when mixed with fermented ginseng concentrate or fermented ginseng powder according to the present invention.
본 발명의 기능성 식품 조성물은 통상의 방법에 따라 건조 분말화하여 충진한 연질 또는 경질 캡슐제, 정제, 과립, 드롭프스 및 티백 형태로 이용될 수 있으 며, 면역증강, 항당뇨 및 항암 효과를 위한 식품에 다양하게 이용될 수 있다. 상기 조성물을 첨가할 수 있는 식품은 이에 한정되지 않지만 예를 들어, 각종 식품류, 음료, 껌, 캔디, 과자류, 차, 비타민 복합제, 건강기능 식품류 등이 될 수 있다. The functional food composition of the present invention can be used in the form of soft or hard capsules, tablets, granules, drops and tea bags filled by dry powdering according to a conventional method, and foods for immune enhancement, antidiabetic and anticancer effects. It can be used in various ways. The food to which the composition can be added is not limited thereto, and may be, for example, various foods, beverages, gums, candy, confectionery, tea, vitamin complexes, health functional foods, and the like.
상기에서 살펴본 바와 같이, 본 발명의 발효인삼농축액 또는 발효인삼분말의 제조방법은 인삼추출액 또는 인삼액에 특정한 조건으로 혼합된 펙티나아제 및 베타갈락토시다아제를 직접 가하여 특정한 조건하에서 발효시킴으로서, 고농도의 IH-901이 함유된 발효인삼농축액 또는 발효인삼분말을 간단하게 제조할 수 있는 방법이며, 또한 본 발명에 의해 제조된 발효인삼농축액 또는 발효인삼분말은 고농도의 IH-901을 함유하고 있어 기능성 식품 조성물로 효과적으로 이용될 수 있다.As described above, the method for preparing fermented ginseng concentrate or fermented ginseng powder according to the present invention is added directly to the ginseng extract or ginseng solution by fermentation under specific conditions by adding fermented pectinase and beta galactosidase under specific conditions. It is a method to easily prepare fermented ginseng concentrate or fermented ginseng powder containing IH-901, and the fermented ginseng concentrate or fermented ginseng powder prepared by the present invention contains high concentration of IH-901 and is a functional food. It can be effectively used as a composition.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<실시예 1><Example 1>
본 발명에 의한 발효인삼농축액의 제조Preparation of Fermented Ginseng Concentrate according to the Present Invention
<1-1> 미삼과 백삼을 이용한 발효인삼농축액의 제조<1-1> Preparation of Fermented Ginseng Concentrate Using Rice and White Ginseng
미삼과 백삼을 각각 5g를 물과 에탄올의 혼합액(1:1의 혼합비, 원료대비 500%)으로 80℃에서 3시간씩 4회 추출한 인삼추출액 7g에 다시 물 100㎖을 가한 후, 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어 50℃, pH 4~5에서 48시간동안 반응시키고 이를 여과한 후 80℃에서 감압 농축하여 본 발명에 의한 발효인삼농축액 6.3g를 제조하였다.Add 100 ml of water to 7 g of ginseng extract extracted 4 times each at 80 ℃ for 3 hours with 5 g of rice and white ginseng mixed with water and ethanol (1: 1 mixing ratio, 500% of raw materials), and then add pectinase and Beta galactosidase was added by 0.3 and 1g, respectively, and reacted for 48 hours at 50 ° C., pH 4-5, and then filtered and concentrated at 80 ° C. to prepare 6.3 g of the fermented ginseng concentrate according to the present invention.
<1-2> 미삼을 이용한 발효인삼농축액의 제조<1-2> Preparation of Fermented Ginseng Concentrate Using Rice Ginseng
미삼 10g를 100㎖의 물로 추출하여 수득한 추출물 7g를 구연산으로 pH 3~4가 되도록 조절한 후, 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어, 50℃에서 48시간동안 반응시키고 이를 여과한 후 농축하여 본 발명에 의한 발효인삼농축액(Ⅰ)을 6.5g를 제조하였다.After extracting 10 g of ginseng with 100 ml of water, 7 g of the extract was adjusted to pH 3-4 with citric acid, followed by 0.3 and 1 g of pectinase and beta galactosidase, respectively, and reacted at 50 ° C. for 48 hours. Let This was filtered and concentrated to prepare 6.5 g of the fermented ginseng concentrate (I) according to the present invention.
또한 미삼 10g를 상기 <실시예 1-1>과 동일한 물과 에탄올의 혼합액으로 추출하여 수득한 추출물 7.2g를 구연산으로 pH 3~4가 되도록 조절한 후, 상기와 동일한 방법으로 반응, 여과 및 농축하여 본 발명에 의한 발효인삼농축액(Ⅱ)을 6.8g를 제조하였다.In addition, after adjusting the extract 7.2g obtained by extracting 10g of ginseng with the same mixture of water and ethanol as in <Example 1-1> to pH 3-4 with citric acid, the reaction, filtration and concentration in the same manner as described above 6.8 g of fermented ginseng concentrate (II) according to the present invention was prepared.
<1-3> 백삼을 이용한 발효인삼농축액의 제조<1-3> Preparation of Fermented Ginseng Concentrate Using White Ginseng
1㎏의 백삼을 5ℓ의 에탄올로 추출하여 수득한 추출물 540g 중 7g를 농축하고 다시 물로 현탁한 후, 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어 상기 <실시예 1-1>과 동일한 방법으로 반응, 여과 및 농축하여 본 발명에 의한 발효인삼농축액 5.2g를 제조하였다.After concentrating 7 g of 540 g of the extract obtained by extracting 1 kg of white ginseng with 5 L of ethanol and suspending it again with water, 0.3 mg and 1 g of pectinase and beta galactosidase were added thereto, respectively. In the same manner as in the reaction, filtration and concentration was prepared 5.2 g of fermented ginseng concentrate according to the present invention.
<1-4> 수삼을 이용한 발효인삼농축액의 제조<1-4> Preparation of Fermented Ginseng Concentrate Using Fresh Ginseng
수삼 6g를 잘게 분쇄하고 멸균한 것을 물로 현탁한 후 구연산으로 pH 3~4.5가 되도록 조절하고, 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어, 50℃에서 72시간 동안 반응시키고 상기 <실시예 1-1>과 동일한 물과 에탄올의 혼합액으로 80℃에서 4시간동안 4회 추출한 다음, 여과한 후 농축하여 본 발명에 의한 발효인삼농축액 3.5g를 제조하였다.Grind fine ginseng 6g and suspend the sterilized with water and adjust to pH 3 ~ 4.5 with citric acid, 0.3, 1g of pectinase and beta galactosidase, respectively, reacted at 50 ℃ for 72 hours Extracted 4 times at 80 ° C. for 4 hours with the same mixture of water and ethanol as in <Example 1-1>, filtered and concentrated to prepare 3.5 g of the fermented ginseng concentrate according to the present invention.
<1-5> 인삼분말을 이용한 발효인삼농축액의 제조<1-5> Preparation of Fermented Ginseng Concentrate Using Ginseng Powder
인삼분말 7g를 물로 현탁한 후 구연산으로 pH 3~4.5가 되도록 조절하고, 상기 <실시예 1-4>와 동일한 방법으로 반응 및 추출한 다음, 여과한 후 농축하여 본 발명에 의한 발효인삼농축액 3.7g를 제조하였다.7 g of ginseng powder was suspended in water, and then adjusted to pH 3 to 4.5 with citric acid. The reaction and extraction were carried out in the same manner as in <Example 1-4>, followed by filtration and concentration of 3.7 g of the fermented ginseng concentrate according to the present invention. Was prepared.
<비교예 1>Comparative Example 1
펙티나아제만을 이용한 발효인삼농축액의 제조Preparation of Fermented Ginseng Concentrate Using Pectinase Only
상기 <실시예 1-1>과 동일한 방법으로 제조된 인삼추출액 7g에 다시 물 100㎖을 가한 후, 펙티나아제 1.3g를 각각 넣고 상기 <실시예 1-1>과 동일한 방법으로 반응 및 감압 농축하여 발효인삼농축액 5.6g를 제조하였다.100 g of water was added to 7 g of ginseng extract prepared in the same manner as in <Example 1-1>, and 1.3 g of pectinase was added thereto. each Put the reaction and concentration under reduced pressure in the same manner as in <Example 1-1> to prepare a fermented ginseng concentrate 5.6g.
<비교예 2>Comparative Example 2
베타갈락토시다아제만을 이용한 발효인삼농축액의 제조Preparation of Fermented Ginseng Concentrate Using Only Beta-galactosidase
상기 <실시예 1-1>과 동일한 방법으로 제조된 인삼추출액 7g에 다시 물 100㎖을 가한 후, 베타갈락토시다아제 1.3g를 각각 넣고 상기 <실시예 1-1>과 동일한 방법으로 반응 및 감압 농축하여 발효인삼농축액 5.4g를 제조하였다.100 g of water was added to 7 g of the ginseng extract prepared in the same manner as in <Example 1-1>, and then 1.3 g of beta galactosidase was added thereto. each Put the reaction and concentration under reduced pressure in the same manner as in <Example 1-1> to prepare a fermented ginseng concentrate 5.4g.
<실험예 1>Experimental Example 1
본 발명에 의한 발효인삼농축액의 IH-901 함량IH-901 content of fermented ginseng concentrate according to the present invention
상기 <실시예 1-1>에서 제조된 본 발명에 의한 발효인삼농축액의 IH-901 함량(20-O-β-D-글루코피라노실-20(S)-프로토파낙사다이올)을 분석하기 위하여 상기 발효인삼농축액 1g를 취하여 수포화 부탄올 60㎖로 3회에 걸쳐 추출한 후, 부탄올 분획을 농축시켜 수득된 농축물 120㎎을 메탄올에 용해시켜 고압액체크로마토그래피를 통하여 IH-901 함량을 분석하고 그 결과를 도 1에 기재하였다.Analyzing IH-901 content (20-O-β-D-glucopyranosyl-20 (S) -protopanaxadiol) of the fermented ginseng concentrate prepared according to the present invention prepared in Example 1-1. 1 g of the fermented ginseng concentrate was extracted three times with 60 ml of saturated butanol, and the concentrated butanol fraction was dissolved in 120 mg of methanol, and the content of IH-901 was analyzed by high pressure liquid chromatography. The result is shown in FIG.
또한 상기 <비교예 1> 또는 <비교예 2>에서 제조된 발효인삼농축액의 IH-901 함량을 상기와 동일한 방법으로 분석하였다.In addition, IH-901 content of the fermented ginseng concentrate prepared in <Comparative Example 1> or <Comparative Example 2> was analyzed in the same manner as above.
한편 상기 <실시예 1-1>에서 제조된 인삼추출액에 대해서도 IH-901 함량을 상기와 동일한 방법으로 분석하였다.Meanwhile, the content of IH-901 was also analyzed in the same manner as above for the ginseng extract prepared in <Example 1-1>.
상기 분석결과를 모두 하기 표 1에 기재하여 비교하였다. All the above analysis results were compared in Table 1 below.
상기 표 1에 기재된 바와 같이, 본 발명에 의한 발효인삼농축액은 인삼추출액에 전혀 존재하진 않는 IH-901을 다량 함유하고 있을 뿐만 아니라, 베타갈락토시다아제만을 투여한 경우에 비하여 3.6배 많은 양을, 펙티나아제만을 투여한 경우에 비하여 1.5배 많은 양을 함유하고 있음을 알 수 있었다.As shown in Table 1, the fermented ginseng concentrate according to the present invention not only contains a large amount of IH-901 which is not present in the ginseng extract, but also contains 3.6 times as much as the beta galactosidase. , It was found that it contained 1.5 times as much as the administration of only pectinase.
<실시예 2><Example 2>
본 발명에 의한 발효인삼분말의 제조Preparation of Fermented Ginseng Powder According to the Present Invention
<2-1> 미삼과 백삼을 이용한 발효인삼분말의 제조<2-1> Preparation of Fermented Ginseng Powder Using Rice and White Ginseng
상기 <실시예 1-1>과 동일한 방법으로 제조된 인삼추출액 7g에 다시 물 100㎖을 가한 후, 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어 50℃, pH4~5에서 24시간동안 반응시키고 80℃에서 감압 건조하여 본 발명에 의한 발효인삼분말 4.23g를 제조하였다.100 ml of water was added to 7 g of the ginseng extract prepared in the same manner as in <Example 1-1>, followed by 0.3 and 1 g of pectinase and beta galactosidase, respectively, at 50 ° C. and pH 4-5. After reacting for an hour and drying under reduced pressure at 80 ° C., 4.23 g of fermented ginseng powder according to the present invention was prepared.
<2-2> 인삼분말을 이용한 발효인삼분말의 제조<2-2> Preparation of Fermented Ginseng Powder Using Ginseng Powder
인삼분말 7g를 물로 현탁한 후 구연산으로 pH 3~4.5가 되도록 조절하고 펙티나아제와 베타갈락토시다아제를 각각 0.3, 1g만큼 넣어, 50℃에서 24시간 동안 반응시키고 상기 <실시예 1-1>과 동일한 물과 에탄올의 혼합액으로 80℃에서 4시간동안 4회 추출한 다음, 그 추출물을 감압 건조하여 본 발명에 의한 발효인삼분말 2.6g를 제조하였다.7 g of ginseng powder was suspended in water, and then adjusted to pH 3 to 4.5 with citric acid, and 0.3 and 1 g of pectinase and beta galactosidase, respectively, were reacted at 50 ° C. for 24 hours, and the <Example 1-1 After extracting 4 times at 80 ° C. for 4 hours with a mixture of water and ethanol, the extract was dried under reduced pressure to prepare 2.6 g of the fermented ginseng powder according to the present invention.
<2-3> 발효인삼농축액을 이용한 발효인삼분말의 제조<2-3> Preparation of Fermented Ginseng Powder Using Fermented Ginseng Concentrate
상기 <실시예 1-1>에서 제조된 발효인삼농축액 150㎎를 60℃까지 가열한 후 1시간 동안 방치하고 화살나무 추출물 50㎎을 추가로 첨가하여 교반시킨 후, 감압 건조하여 85%의 발효인삼추출물이 함유된 발효인삼분말 100㎎을 제조하였다.150 mg of the fermented ginseng concentrate prepared in <Example 1-1> was heated to 60 ° C. and left for 1 hour, and further stirred by adding 50 mg of arrowwood extract, followed by drying under reduced pressure. 100 mg of fermented ginseng powder containing the extract was prepared.
도 1은 본 발명에 의한 발효인삼농축액을 고압 액체 크로마토그래피를 수행한 결과를 나타낸 그래프이다.1 is a graph showing the results of performing high pressure liquid chromatography on the fermented ginseng concentrate according to the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070132389A KR100954851B1 (en) | 2007-12-17 | 2007-12-17 | Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070132389A KR100954851B1 (en) | 2007-12-17 | 2007-12-17 | Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090064988A KR20090064988A (en) | 2009-06-22 |
KR100954851B1 true KR100954851B1 (en) | 2010-04-28 |
Family
ID=40993464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070132389A KR100954851B1 (en) | 2007-12-17 | 2007-12-17 | Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100954851B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101458344B1 (en) * | 2014-05-30 | 2014-11-04 | 주식회사 일화 | Preparation method of ginseng hydrolysate concentrate or powder having high concentration of ih-901 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR870000031A (en) * | 1985-06-17 | 1987-02-16 | 마쯔소노 나오미 | Extraction method of Korean ginseng extract |
KR20020040533A (en) * | 2001-05-15 | 2002-05-30 | 카부시키가이샤토오요오핫코오 | Method of lowering molecular weight of effective components in Red Ginseng Extract |
-
2007
- 2007-12-17 KR KR1020070132389A patent/KR100954851B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR870000031A (en) * | 1985-06-17 | 1987-02-16 | 마쯔소노 나오미 | Extraction method of Korean ginseng extract |
KR20020040533A (en) * | 2001-05-15 | 2002-05-30 | 카부시키가이샤토오요오핫코오 | Method of lowering molecular weight of effective components in Red Ginseng Extract |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101458344B1 (en) * | 2014-05-30 | 2014-11-04 | 주식회사 일화 | Preparation method of ginseng hydrolysate concentrate or powder having high concentration of ih-901 |
Also Published As
Publication number | Publication date |
---|---|
KR20090064988A (en) | 2009-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100992800B1 (en) | A process for preparing novel processed ginseng or extract thereof showing increased amount of minor ginsenosides | |
KR101374026B1 (en) | Fermented ginseng containing bio-conversed ginsenoside metabolites increased by co-fermentation of fungi and lactic acid bacteria | |
JP6170674B2 (en) | Method for producing fermented ginseng concentrate or powder | |
KR20170061959A (en) | Preparation method of fermented ginseng and fermented black-red ginseng with active ginsenoside heightening rate absorption | |
KR101651082B1 (en) | A Composition Comprising the Fermentate of Puerariae Radix extract for protecting liver damage | |
KR100555652B1 (en) | Extract of processed Panax Species plant, process for preparing the same, and composition containing the same for preventing and treating cancer and allergy- mediated disease | |
KR100954851B1 (en) | Preparation method of fermented ginseng concentrate or powder having high concentration of IH-901 | |
KR102069996B1 (en) | Method for producing water-soluble drug composition containing high concentration of hydrophobic ginsenoside | |
KR102234567B1 (en) | New C-p-hydroxybenzylflavonol glycosides from Pumpkin's Tendrile and Their Uses | |
Chi et al. | Differential transformation of ginsenosides from Panax ginseng by lactic acid bacteria | |
KR102531825B1 (en) | Method Preparing Ginsenosides F2 or Rg3 Using Fruits of Panax ginseng | |
US8541035B2 (en) | Methods for preparing a fermented ginseng concentrate or powder | |
KR20110052218A (en) | Preparation method of ginseng and red ginseng concentrate containing the increased amount of compound k by using pectinex | |
KR102394399B1 (en) | Composition for improving cognitive function | |
KR101718351B1 (en) | Novel Paenibacillus sp. RMKS 72, fermented ginseng using the same and composition having anti-oxidant activity comprising extract of fermented ginseng using the same | |
KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR20040020693A (en) | A new process for enhancing the efficacy of Ginseng extract | |
KR101975018B1 (en) | Composition for lowering cholesterol comprising a mixture culture of Ginseng Berry-Auricularia auricula mycelia | |
KR101470347B1 (en) | A Composition Comprising the Fermentate of Scutellariae Radix extract for protecting liver damage | |
KR101458344B1 (en) | Preparation method of ginseng hydrolysate concentrate or powder having high concentration of ih-901 | |
KR20050097710A (en) | Modified ginsenoside mixture which has selective anti-lung cancer activity | |
KR102582772B1 (en) | Method for Preparing Fermented Ginseng with Increased Ginsenosides | |
KR100533505B1 (en) | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
KR101975017B1 (en) | Composition for lowering cholesterol comprising a mixture culture of Ginseng Berry-hongguk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |